-
July 11th, 2023: Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers. BOSTON, July 11th, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class […]
-
May 9th, 2023: Ratio Therapeutics Announces Opening of New Research and Development Facility
Boston-based fast-growing radiopharmaceutical company opens the doors to its new headquarters and research facility to advance targeted radiotherapies for cancer BOSTON, May 9, 2023 – Ratio Therapeutics Inc., a pharmaceutical company focused on developing innovative radiopharmaceuticals for the treatment of cancer, is pleased […]
-
March 28th, 2023: Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications BOSTON, March 28, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment […]
-
March 13th, 2023: Ratio Therapeutics Appoints Dr. Noel Monks as Head of Biology
BOSTON, March 13, 2023 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, today announced the appointment of Dr. Noel Monks as the company’s Head of Biology. Dr. Monks joins Ratio with over 20 years […]
-
February 1, 2023: Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment
Boston-Based Pharmaceutical Company Brings Total Financing to More Than $40 Million since 2022 Launch Dr. Susan K. Whoriskey, Ph.D., to Join the Company’s Board of Directors as Strategic Advisor BOSTON, February 1, 2023 – Ratio Therapeutics Inc., a pharmaceutical company specializing in the […]
-
December 6, 2022: Ratio Therapeutics Appoints Reed Malleck as Chief Financial Officer
BOSTON, December 6, 2022 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Reed Malleck as the company’s Chief Financial Officer (CFO). […]
-
September 15, 2022: Ratio Therapeutics Appoints Jacob Hesterman, Ph.D., as Chief Data Officer
BOSTON, September 15, 2022 – Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Jacob Hesterman, Ph.D., as the company’s Chief Data Officer (CDO). […]
-
July 6, 2022: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
Berlin, 6 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225. The agreement covers the development of […]
-
June 10, 2022: Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers
Company Emerges from Stealth Mode with More Than $20 Million in Seed Financing and Fully Funded Development Alliances with Bayer and Lantheus BOSTON, June 10, 2022 /PRNewswire/ — Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial […]
